NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CannAssist International Corp. (OTCQB: CNSC), a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Read more from the original source:
InvestorBrandNetwork (IBN) Coverage Initiated for CannAssist International Corp.

JERSEY, Channel Islands, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application for the Initial Serological Disease Screening Microarray (SDS) and MosaiQ instrument. The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray. In response to this request, the Company intends to re-submit its application, with the additional data requested by the FDA, in early 2021. Following that submission, the Company is targeting to receive the FDA 510(k) clearance in mid-2021.

Read more from the original source:
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

WINNIPEG, Manitoba, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce the commercial launch of its DermaKB™ shampoo, shampoo bar and scalp detoxifier as the first products in their new skin care line.

See the original post here:
Kane Biotech Announces Launch of New Human Health OTC DermaKB™ Product Line

--Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy

Read the original post:
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual...

Follow this link:
Bespoke Extracts to Sponsor Professional Mixed Martial Artist Cody Law in Bellator 254

MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previously announced acquisition of Synteract, a leading full-service CRO focused on the rapidly growing, emerging biopharma segment.

More:
Syneos Health Completes Acquisition of Synteract

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.8 million payment as part of an expected $1.7 million in payments under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payments are part of an original non-dilutive grant of up to $18.7 million awarded in 2016 to support Salarius’ operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers. Seclidemstat is a reversible LSD1 inhibitor being studied in two clinical trials — one trial in relapsed/refractory Ewing sarcoma, a rare and deadly pediatric bone cancer, and a second trial in advanced solid tumors (AST).

Follow this link:
Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

NEW YORK and MAINZ, GERMANY, December 10, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicine has published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. In the trial of 43,448 participants, who were 16 years and older, 21,720 of whom received BNT162b2 and 21,728 placebo, the two-dose regimen of 30 mg BNT162b2, which was given 21 days apart, was well-tolerated and demonstrated vaccine efficacy of 95% against COVID-19.

Read this article:
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of...

LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France

See original here:
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2020

Results provide insight into potential disease modifying effects of CNM-Au8 for the treatment of ALS patients Results provide insight into potential disease modifying effects of CNM-Au8 for the treatment of ALS patients

More here:
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MND

NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Better Choice Company (OTCQB: BTTR) (“Better Choice”), an animal health and wellness company, is pleased to announce that Michael Young (Chairman), Damian Dalla-Longa (EVP Capital Markets & Corporate Development), and Rob Sauermann (EVP, Finance & Strategy) will present to a live virtual audience at the LD Micro Main Event (XIII) on December 14, 2020 at 4:20 p.m. ET.

The rest is here:
Better Choice Company to Present at LD Micro Main Event Virtual Conference on December 14th

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a public offering of its ordinary shares (or pre-funded warrants in lieu thereof). All of the ordinary shares (or pre-funded warrants in lieu thereof) in the offering will be sold by Nabriva Therapeutics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read this article:
Nabriva Therapeutics Announces Proposed Public Offering

BOCA RATON, Fla., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Micron Medical (“Micron” or “the Company”), a privately-held, commercial stage medical device company preparing to launch a revolutionary minimally invasive neurostimulator for treating patients suffering with an overactive bladder (OAB), today announced that it will be presenting at the 13th Annual LD Micro Main Event virtual investor conference on Monday, December 14, at 3:00 PM EST / 12:00 PM PST.

View original post here:
Micron Medical to Present at the 13th Annual LD Micro Main Event Virtual Conference

GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that all resolutions were passed by requisite majority at its annual general meeting (“AGM”) held earlier today in New Haven, Conn., United States.

See more here:
Bioasis Announces Annual General Meeting Results

LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the JMP Securities Hematology Summit Tuesday December 15th at 1:30pm EST /06:30pm GMT /7:30pm CET. The format will be a “fireside chat” discussion hosted by  JMP Securities' Reni Benjamin.

Read the original post:
ERYTECH to Present at the JMP Securities Hematology Summit

Orphazyme A/SCompany announcement                                                                                         No. 72/2020Inside informationCompany Registration No. 32266355

More:
Kim Stratton, CEO, resigns from Orphazyme

MALVERN, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020 to provide its stockholders additional time to vote on the proposals submitted for stockholder approval at the meeting.

See original here:
Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”) at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses.

Excerpt from:
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock

NEW YORK and MAINZ, GERMANY, December 10, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support of the FDA granting Emergency Use Authorization (EUA) for the companies’ COVID-19 mRNA vaccine (BNT162b2). There is one member of the Committee whose vote is not included in the 17 to 4 vote decision.

Read the rest here:
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the...

PHOENIX, Dec. 10, 2020 /PRNewswire/ --Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company's ImmCelz product at generating what is termed in the field of immunology as "infectious tolerance."

Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz administration caused generation of T regulatory cells and tolerogenic dendritic cells. Both of these cell types have previously been described to possess ability to suppress autoimmunity.

"In 2003, Dr. Weiping Min from the University of Western Ontario and myself published a paper describing the Tolerogenic Loop, in which we were able to perform fully mis-matched cardiac transplants without need for long term immune suppression1." Said Dr. Thomas Ichim, Chief Scientific Officer of the Company. "We are extremely enthusiastic to discover that ImmCelz, which is a personalized immunotherapy can induce similar biological processes and in this case suppress autoimmunity."

Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"Given that our issued intellectual property covers multi-billion dollar markets, it is critical in our development plans to establish scientific mechanisms of action. By understanding how our products work at a cellular and molecular level, we feel we have an advantage when engaging Big Pharma in discussions for licensing/partnering interactions." Said Timothy Warbington, President and CEO of the Company.

The company intends to publish an update on the overall 2020 activities in the coming weeks.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Timothy Warbington, CEO[emailprotected] CreativeMedicalHealth.com

Creativemedicaltechnology.comwww.StemSpine.comwww.Caverstem.comwww.Femcelz.com

1 https://www.jimmunol.org/content/170/3/1304

SOURCE Creative Medical Technology Holdings, Inc.

Home

Follow this link:
Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz Cellular...